Dimensional Fund Advisors LP raised its stake in shares of Maximus, Inc. (NYSE:MMS) by 3.2% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 632,118 shares of the health services provider’s stock after buying an additional 19,788 shares during the period. Dimensional Fund Advisors LP owned about 0.98% of Maximus worth $39,318,000 as of its most recent filing with the SEC.
Several other hedge funds have also modified their holdings of MMS. Globeflex Capital L P acquired a new stake in shares of Maximus during the first quarter valued at approximately $1,192,000. Liberty Mutual Group Asset Management Inc. boosted its stake in Maximus by 1.8% in the first quarter. Liberty Mutual Group Asset Management Inc. now owns 29,118 shares of the health services provider’s stock worth $1,810,000 after buying an additional 517 shares in the last quarter. Geode Capital Management LLC boosted its stake in Maximus by 6.9% in the first quarter. Geode Capital Management LLC now owns 496,870 shares of the health services provider’s stock worth $30,905,000 after buying an additional 31,918 shares in the last quarter. Cambridge Investment Research Advisors Inc. purchased a new stake in Maximus during the first quarter worth approximately $393,000. Finally, Vanguard Group Inc. boosted its stake in Maximus by 8.0% in the first quarter. Vanguard Group Inc. now owns 5,538,187 shares of the health services provider’s stock worth $344,476,000 after buying an additional 411,521 shares in the last quarter. Institutional investors own 97.20% of the company’s stock.
Shares of Maximus, Inc. (MMS) traded down 0.08% on Friday, hitting $59.30. 301,822 shares of the stock traded hands. Maximus, Inc. has a 52 week low of $43.69 and a 52 week high of $64.97. The stock has a 50 day moving average price of $60.78 and a 200-day moving average price of $61.00. The stock has a market cap of $3.85 billion, a price-to-earnings ratio of 19.01 and a beta of 1.39.
Maximus (NYSE:MMS) last announced its quarterly earnings results on Thursday, August 3rd. The health services provider reported $0.79 earnings per share for the quarter, topping the consensus estimate of $0.76 by $0.03. Maximus had a net margin of 8.43% and a return on equity of 25.08%. The company had revenue of $600.40 million for the quarter, compared to analysts’ expectations of $614.12 million. During the same quarter in the previous year, the business posted $0.79 earnings per share. Maximus’s quarterly revenue was down 2.7% on a year-over-year basis. On average, equities research analysts forecast that Maximus, Inc. will post $3.12 EPS for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Thursday, August 31st. Investors of record on Tuesday, August 15th will be given a $0.045 dividend. This represents a $0.18 annualized dividend and a yield of 0.30%. The ex-dividend date is Friday, August 11th. Maximus’s dividend payout ratio is presently 5.73%.
ILLEGAL ACTIVITY WARNING: This piece was originally published by BNB Daily and is the property of of BNB Daily. If you are viewing this piece on another publication, it was illegally copied and republished in violation of international copyright law. The legal version of this piece can be viewed at https://www.baseball-news-blog.com/2017/08/19/maximus-inc-nysemms-shares-bought-by-dimensional-fund-advisors-lp-updated-updated-updated.html.
A number of brokerages recently weighed in on MMS. KeyCorp reaffirmed a “sector weight” rating on shares of Maximus in a research note on Thursday, May 25th. ValuEngine lowered shares of Maximus from a “buy” rating to a “hold” rating in a research note on Tuesday, May 16th. Canaccord Genuity downgraded shares of Maximus from a “buy” rating to a “hold” rating and set a $62.00 price objective for the company. in a research note on Tuesday, July 4th. BidaskClub downgraded shares of Maximus from a “strong-buy” rating to a “buy” rating in a research note on Thursday, July 6th. Finally, Zacks Investment Research upgraded shares of Maximus from a “sell” rating to a “hold” rating in a research note on Wednesday, July 26th. One equities research analyst has rated the stock with a sell rating and eight have assigned a hold rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $62.17.
In other Maximus news, CEO Richard A. Montoni sold 30,000 shares of the business’s stock in a transaction on Thursday, May 25th. The shares were sold at an average price of $62.81, for a total transaction of $1,884,300.00. Following the transaction, the chief executive officer now owns 584,114 shares in the company, valued at $36,688,200.34. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, President Bruce Caswell sold 8,000 shares of the business’s stock in a transaction on Tuesday, May 23rd. The shares were sold at an average price of $62.76, for a total transaction of $502,080.00. Following the sale, the president now directly owns 35,904 shares of the company’s stock, valued at $2,253,335.04. The disclosure for this sale can be found here. Insiders sold 154,342 shares of company stock worth $9,516,217 in the last 90 days. 3.10% of the stock is currently owned by company insiders.
Maximus Company Profile
MAXIMUS, Inc provides business process services (BPS) to government health and human services agencies. The Company operates through three segments: U.S. Federal Services, Health Services and Human Services. The U.S. Federal Services segment provides BPS and program management for large government programs, independent health review and appeals services for both the United States Federal Government, and state-based programs and technology solutions for civilian federal programs.
Receive News & Ratings for Maximus Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maximus Inc. and related companies with MarketBeat.com's FREE daily email newsletter.